Paper Details

  1. Home
  2. Paper Details

Molecular Targeted Therapies of Aggressive Thyroid Cancer.

Author: AntonelliAlessandro, BaldiniEnke, FallahiPoupak, FerrariSilvia Martina, MaterazziGabriele, MiccoliPaolo, PolittiUgo, UlisseSalvatore

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Tyrosine kinase inhibitors (TKIs) are emerging as new therapies for aggressive thyroid cancers, including differentiated thyroid carcinomas (DTCs) and medullary thyroid cancer (MTC). Vandetanib and cabozantinib are approved for MTC, while sorafenib and lenvatinib are approved for DTC refractory to radioiodine.
Paper Details　
Original Abstract of the Article :
Differentiated thyroid carcinomas (DTCs) that arise from follicular cells account >90% of thyroid cancer (TC) [papillary thyroid cancer (PTC) 90%, follicular thyroid cancer (FTC) 10%], while medullary thyroid cancer (MTC) accounts <5%. Complete total thyroidectomy is the treatment of choice for PTC,...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4653714/

データ提供：米国国立医学図書館（NLM）

Molecular Targeted Therapies: Navigating the Desert of Aggressive Thyroid Cancer

Imagine thyroid cancer as a treacherous desert landscape, where aggressive and metastatic tumors can quickly spread. This study explores the potential of molecular targeted therapies, like building a series of oases, to combat these aggressive forms of thyroid cancer. The authors delve into the complex landscape of thyroid cancer, highlighting the genetic alterations and molecular pathways involved in its development and progression. They discuss the role of tyrosine kinase inhibitors (TKIs), which target specific signaling pathways involved in tumor growth, angiogenesis, and spread. The researchers review the current status of TKIs in treating aggressive thyroid cancer, including DTC, MTC, and anaplastic thyroid cancer, and discuss their clinical efficacy and side effects.

A New Oasis in the Desert of Treatment Resistance

The study highlights the emergence of TKIs as promising new therapies for aggressive thyroid cancer. These targeted agents, like strategic oases in the desert, can potentially interrupt the growth and spread of tumors, offering a glimmer of hope for patients with advanced disease.

Navigating the Desert of Challenges

The authors acknowledge the challenges associated with TKI therapy, including potential side effects and the need for personalized treatment approaches. Continued research is crucial to develop new and more effective TKIs, to identify biomarkers that can predict patient response, and to optimize treatment strategies.

Dr. Camel's Conclusion

The desert of aggressive thyroid cancer can be a daunting landscape, but this study offers a beacon of hope. Molecular targeted therapies, like carefully chosen oases, hold promise for combating these challenging tumors. Continued research is essential to refine these therapies and improve patient outcomes, paving the way for more effective treatments and ultimately, a better future for those facing this disease.

Date :
  1. Date Completed 2015-12-04
  2. Date Revised 2020-12-26
Further Info :

Pubmed ID

26635725

DOI: Digital Object Identifier

PMC4653714

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.